TET2 and neoplasm: However, loss of TET2 significantly decreased the ability of Vit-C to activate tumor-infiltrating CD8+ and CD3+ cells, indicating that TET2 is the primary target for Vit-C in enhancing the effectiveness of the anti-PD-L1 therapy [200].